Issues and controversies of hepatocellular carcinoma-targeted therapy clinical trials in Asia: experts' opinion
Publication in refereed journal


Times Cited
Web of Science31WOS source URL (as at 24/11/2020) Click here for the latest count
Altmetrics Information
.

Other information
AbstractAsia has a disproportionate share of the world's burden of hepatocellular carcinoma (HCC). However, the highly regarded clinical practice guidelines and recommendations for the design and conduct of clinical trials for HCC largely reflect Western practice. In order to design mutually beneficial international clinical trials of promising targeted therapies, it is imperative to understand how the aetiology, staging and treatment of HCC differ between Asian and Western countries. Our group, comprising experts in oncology and hepatology from countries that constitute the Eastern Asian region, convened to compare and contrast our current practices, evaluate potential compliance with the clinical trial recommendations, and offer suggestions for modifications that would enhance international collaboration. Here, we describe the results of our discussions, including recommendations for appropriate patient stratification based on potentially important differences in HCC aetiology, identification of practices that may confound interpretation of clinical trial outcomes (traditional Chinese medicine; antivirals that target hepatitis B virus; heterogeneous embolization procedures), suggestions for utilizing a common staging system in study protocols, recognition that sorafenib usage is limited by financial constraints and potentially increased toxicity in Asian patients, and expansion of patient populations that should be eligible for initial clinical trials with new agents.
All Author(s) ListChen PJ, Furuse J, Han KH, Hsu CU, Lim HY, Moon H, Qin SK, Ye SL, Yeoh EM, Yeo W
Journal nameLiver International
Detailed description[Epub ahead of print]
Year2010
Month11
Day1
Volume Number30
Issue Number10
PublisherWiley: 12 months
Pages1427 - 1438
ISSN1478-3223
eISSN1478-3231
LanguagesEnglish-United Kingdom
Keywordsantineoplastic agents; Asia; clinical practice patterns; clinical trials; hepatocellular carcinoma; liver neoplasms
Web of Science Subject CategoriesGastroenterology & Hepatology; GASTROENTEROLOGY & HEPATOLOGY

Last updated on 2020-24-11 at 23:54